Is the Cash on the Sidelines Ready for a Rally?

This week, we've brought back Stansberry Venture Technology editor Dave Lashmet.

Dave mines the markets for lucrative opportunities in publicly traded, small-cap companies. A typical "diamond in the rough" might pioneer a revolutionary new drug or technology. These early-stage innovators can potentially change the world for the better – and rake in outsized gains for investors. And the best part about investing in these kinds of companies lies in their resilience to bear markets like today's...

Dave rejoins us today with a special look into some of the most promising new trends in the biotech space. You'll hear about a leader in robotic surgery... cutting-edge radiation therapy that Dave has been tracking for several years... new breakthroughs in cancer treatment... and the true story – one that leaves Dan momentarily speechless – of a man who overcame life-changing, traumatic injuries to become a crusader for patient rights.